Dexcom 5 reduces hypos more than FreeStyle Libre in type 1 diabetes trial

The Dexcom G5 steady glucose monitor outperformed the FreeStyle Libre for decreasing hypoglycemia in folks with type 1 diabetes, a brand new trial has revealed.

In the I HART (Impact on Hypoglycemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data) research, the Dexcom G5 was in comparison with the FreeStyle Libre, which is a flash glucose monitoring system, for time spent in hypoglycemia and worry of hypos.

The 40 type 1 diabetes individuals concerned had hypo unawareness or an episode of extreme hypoglycemia throughout the final 12 months. They have been all beforehand on a routine of a number of each day injections (MDI) of insulin.

The individuals have been randomised to obtain both the Dexcom G5 or Libre and monitored over a interval of eight weeks.

As properly as spending much less time in hypoglycemia, Dexcom G5 customers had much less worry of hypoglycemia and higher blood sugar management in a single day.

The research is critical not as a result of it demonstrates downsides of the Libre – the gadget is extensively thought to be a significant enchancment on blood glucose testing – however as a result of the CGM advantages displayed are clinically related and will affect future assist for utilizing CGMs in folks with hypo unawareness.

The Dexcom G5 has the benefit of constantly monitoring glucose ranges and has alarms to alert the consumer when glucose ranges are dropping quickly or are about to go too low. The FreeStyle Libre can not alert folks mechanically in this fashion, nevertheless, just like the Dexcom G5, it permits folks to evaluation traits and verify sugar ranges a lot more simply than is feasible with blood glucose assessments alone.

“This impactful study highlights the importance of innovative technologies in managing a challenging long-term condition which has serious health and psychological outcomes for young people,” mentioned lead writer Nick Oliver, Imperial College London.

“It supports the role of real-time CGM devices with alerts and alarms in the clinical pathway for people with type 1 diabetes, especially those with a high risk of hypoglycaemia and impaired hypoglycaemia awareness.”

John Lister, General Manager, Dexcom EMEA, added: “We are delighted that the Dexcom G5 Mobile CGM System was able to demonstrate such a significant reduction in hypoglycemia both during the day and at night, while also reducing the fear associated with hypoglycaemia.”

The findings have been revealed in Diabetic Medicine.